Replimune Group, Inc.
REPLNext catalyst
RP2 Injection
High-Risk Oral Precancerous Disease
Get an email about REPL's next catalysts
Track Replimune Group (REPL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (PDUFA date).See the timeline
2 upcoming, 1 past
RP2 Injection Phase 2 Est. Readout (INTERCEPT)
Estimated primary completion for RP2 Injection trial (NCT06623110) in High-Risk Oral Precancerous Disease. Topline data typically follows completion by weeks to months.
SourceFDA PDUFA Date RP1
For advanced melanoma. BLA submitted. AI-extracted from: Replimune will again submit its melanoma drug for approval
SourceHow REPL's past catalysts played out
Market Overview
Stock performance and key metrics
RP2
Metastatic Uveal Melanoma
Vusolimogene Oderparepvec
Advanced Melanoma
RP1
Non-Small Cell Lung Cancer (NSCLC)
RP1, intra-tumoral injection, oncolytic virus
Cutaneous Squamous Cell Carcinoma
RP2 Injection
High-Risk Oral Precancerous Disease
RP3
Refractory Metastatic Colorectal Cancer
Vusolimogene Oderparepvec (VO)
Angiosarcoma
RP2 Monotherapy
Hepatocellular Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
RP2 | Phase 3 | Metastatic Uveal Melanoma | - | - |
Vusolimogene Oderparepvec | Phase 3 | Advanced Melanoma | - | - |
RP1 | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | - | - |
RP1, intra-tumoral injection, oncolytic virus | Phase 2 | Cutaneous Squamous Cell Carcinoma | - | - |
RP2 Injection | Phase 2 | High-Risk Oral Precancerous Disease | - | - |
RP3 | Phase 2 | Refractory Metastatic Colorectal Cancer | - | - |
Vusolimogene Oderparepvec (VO) | Phase 2 | Angiosarcoma | - | - |
RP2 Monotherapy | Phase 2 | Hepatocellular Carcinoma | - | - |
melanoma
2 drugs in this indication
cutaneous melanoma
1 drug in this indication
Advanced melanoma
1 drug in this indication
Unresectable Advanced Cutaneous Melanoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Replimune Group, Inc.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in Replimune Group, Inc.'s (REPL) pipeline across Phase 3, Phase 2. Its lead program is RP1 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Replimune Group, Inc.'s next FDA catalyst?→
Replimune Group, Inc.'s (REPL) next tracked catalyst is a Phase 2 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track REPL biotech catalysts?→
Add REPL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Replimune Group, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.